The Food and Drug Administration has finally approved a first-of-its-kind treatment for vitiligo. 🎊🎉 Opzelura (1,5% ruxolitinib cream) is the only one approved in the U.S. or E.U. to restore skin color in people with the most common, non-segmental form of vitiligo. The medication is approved for continuous topical use in ages 12+, twice daily to affected areas of up to 10% body surface area, with no limits on usage duration or areas of application, — as long as patients continue to see benefit. Incyte noted it could take up to 24 weeks for Opzelura to work for some vitiligo patients, yet satisfactory outcomes may require treatment for up to one year. The FDA approval of Opzelura for vitiligo will start a full-scale commercial roll-out and marketing campaign within a few months, but Incyte is also eyeing European approval for vitiligo treatment for as early as the end of this year.